

AMGEN INC  
Form 8-K  
October 14, 2011

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of The**

**Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported)**

**October 13, 2011**

**AMGEN INC.**

**(Exact name of registrant as specified in its charter)**

Edgar Filing: AMGEN INC - Form 8-K

(State or other Jurisdiction  
of Incorporation)

(Commission  
File Number)

(IRS Employer  
Identification Number)

**Amgen Inc.**

**One Amgen Center Drive**

**Thousand Oaks, CA**  
(Address of principal executive offices)  
**805-447-1000**

**91320-1799**  
(Zip Code)

(Registrant's telephone number, including area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

(d) Election of Directors.

On October 13, 2011, the Board of Directors (the Board) of Amgen Inc. (the Company) increased the size of its Board from twelve to thirteen members and appointed Robert A. Bradway, the Company's President and Chief Operating Officer, as a director of the Company, effective immediately. Mr. Bradway will not receive any additional compensation for serving as a director and will not serve on any committees of the Board.

There are no other relationships or transactions between Mr. Bradway (or any member of his immediate family) and the Company (or any of its subsidiaries) and there is no arrangement or understanding between Mr. Bradway and any other persons or entities pursuant to which Mr. Bradway was appointed as a director of the Company.

The full text of the press release announcing Mr. Bradway's appointment is furnished as Exhibit 99.1 to this Current Report on Form 8-K and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

Exhibit Number	Document Description
99.1	Press release dated October 13, 2011.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AMGEN INC.

Date: October 13, 2011

By: /s/ David J. Scott  
Name: David J. Scott  
Title: Senior Vice President,

General Counsel and Secretary

**EXHIBIT INDEX**

Exhibit Number	Document Description
99.1	Press release dated October 13, 2011.